Single-agent adjuvant chemotherapy did not improve overall survival when compared to no adjuvant chemotherapy.

The FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice regulations for active pharmaceutical ingredients.

Nivolumab plus ipilimumab prolonged PFS when compared to nivolumab alone in patients with MSI-H/dMMR unresectable or ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Adding pamrevlumab to chemotherapy did not improve survival in patients with previously untreated, locally advanced pancreatic cancer.

Neoadjuvant CRT plus sintilimab yielded a higher pCR rate than neoadjuvant chemo plus sintilimab in patients with locally advanced ESCC.

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

I call it cancer — the cancer caused by the Biden administration,” Trump told reporters.

Policies that improve payer coverage, streamline authorization processes, and reduce cost-sharing burdens for medical equipment are urgently needed,” according to researchers.

President Donald Trump’s early actions on health care signal his likely intention to wipe away some Biden-era programs to lower drug costs and expand coverage under public insurance programs.

The FDA has approved Grafapex (treosulfan) for use in combination with fludarabine as a preparative regimen for allogeneic HSCT in patients aged 1 year and older with AML or MDS.

Adding intraperitoneal paclitaxel to intravenous paclitaxel and oral S-1 improved survival in patients with gastric cancer and peritoneal metastasis.